Nektar Therapeutics has released its financial results for the third quarter of 2026, revealing a pivotal moment for the company as it advances its drug rezpegaldesleukin into Phase 3 clinical trials. The report indicates a significant increase in cash reserves, but a decline in revenue, reflecting the challenges and opportunities within the pharmaceutical preparations industry.
The company, based in San Francisco, California, operates under the ticker NKTR on the Nasdaq exchange. Nektar Therapeutics specializes in pharmaceutical preparations, as classified under SIC 2834. Recent filings show that the company is actively engaged in research and development, which is critical for its future growth.
According to the filing dated November 12, 2026, the company reported cash and investments in marketable securities totaling $952.9 million, a substantial increase from $245.8 million at the end of 2025. However, revenue for the third quarter was $9.4 million, down from $11.8 million during the same period last year. For the first nine months of 2026, revenue reached $30.4 million, compared to $33.4 million in 2025.
In the filing, the company stated, “This was a pivotal quarter for Nektar as we moved rezpegaldesleukin quickly into Phase 3 development.” The drug is being evaluated for its potential in treating atopic dermatitis and alopecia areata, with the company initiating all three global ZENITH AD registrational trials for atopic dermatitis and planning to start trials for alopecia areata in December.
The filing also highlighted total operating costs and expenses of $67.2 million for the third quarter, compared to $43.5 million in the same quarter of 2025. This increase is attributed to rising research and development expenses, which amounted to $44.1 million in the third quarter, up from $27.3 million in the previous year. The company is investing heavily in its clinical programs, particularly in support of the Phase 3 ZENITH AD program.
Despite the increased investment in R&D, Nektar reported a net loss of $55.7 million for the third quarter, equating to a basic and diluted net loss per share of $1.63. This is compared to a net loss of $35.5 million or $1.87 per share in the same quarter of 2025. The company’s net loss for the first nine months of 2026 was $141.2 million, compared to $128.0 million in the prior year.
The results reflect the broader trends in the pharmaceutical industry, where companies are increasingly focusing on innovative treatments and clinical trials. Nektar's commitment to advancing rezpegaldesleukin is indicative of its strategy to capture market share in the competitive landscape of chronic autoimmune disease therapies.
Looking ahead, Nektar Therapeutics is set to continue its clinical trials, with topline data expected in mid-2028 and a BLA submission targeted for 2029. The filing does not specify any immediate next steps beyond the ongoing clinical development.
This update will be closely watched by industry analysts and competitors, as it underscores the financial dynamics and strategic directions within the pharmaceutical preparations sector.
Read Next
Madison Technologies reports Q3 results with net loss
Cyberloq Technologies Releases Q3 Results Amid Challenges
Specificity, Inc. Reports Q3 2026 Financial Results
SUNation Energy reports Q3 2026 financial results
Vystar Corp reports on Q3 performance in latest filing
Alpex Acquisition Corp Reports Quarterly Results










